Edition:
United States

ESSA Pharma Inc (EPIX.OQ)

EPIX.OQ on NASDAQ Stock Exchange Capital Market

0.22USD
13 Dec 2017
Change (% chg)

-- (--)
Prev Close
$0.22
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
31,543
52-wk High
$3.59
52-wk Low
$0.21

Summary

Name Age Since Current Position

Richard Glickman

57 2016 Chairman of the Board

David Parkinson

67 2016 President, Chief Executive Officer, Director

David Wood

57 Chief Financial Officer

Peter Virsik

2016 Chief Operating Officer, Executive Vice President

Raymond Andersen

67 2016 Chief Technology Officer, Director

Marianne Sadar

53 Chief Scientific Officer, Director

Frank Perabo

50 2014 Chief Medical Officer

Franklin Berger

67 2016 Director

Scott Requadt

2016 Director

Gary Sollis

61 2016 Director

Biographies

Name Description

Richard Glickman

Dr. Richard M. Glickman, LL.D. Chairman of the Board of the Company. As the Chairman of the Board, Dr. Glickman is responsible for the management of the Board to ensure the Company has appropriate objectives and an effective strategy, and that it is operating in accordance with a high standard of corporate governance. Dr. Glickman has a part-time role with ESSA and does not have an employment agreement. Dr. Glickman was a co-founder, Chairman and Chief Executive Officer of Aspreva Pharmaceuticals Inc. (“Aspreva”) which was acquired by the Galenica group for $915M. Prior to establishing Aspreva, Dr. Glickman was the co-founder and Chief Executive Officer of StressGen Biotechnologies Corporation. Dr. Glickman currently serves on Cardiome Pharma Corp.’s Board of Directors as a member of the Compensation Committee and as its lead independent director. In addition, Dr. Glickman serves as Chairman of the Board of Aurinia Pharmaceuticals Inc. and as a Director of Vida Pharmaceuticals and Engene Inc. In addition, he has served on numerous biotechnology boards including roles as Chairman of Life Sciences B.C. (formerly the British Columbia Biotechnology Alliance), Director of the Canadian Genetic Diseases Network (a Canadian Centre of Excellence), a member of the federal government’s National Biotechnology Advisory Committee, a member of the British Columbia Innovation Council and a director for the Vancouver Aquarium and Chair of its Research Committee. Dr. Glickman received the Ernst & Young Entrepreneur of the Year 2004 Award for the Pacific Region Life Sciences Group, both Canada’s and British Columbia’s Top 40 under 40 Award for Entrepreneurs, the 2006 BC Biotech Leadership Award and the Lupus Foundation of America Leadership Award.

David Parkinson

Dr. David Ross Parkinson, M.D., is President, Chief Executive Officer, Director of the Company. He was an Independent Director of ESSA Pharma Inc. Dr. Parkinson is a venture partner at New Enterprise Associates (NEA). From 2007 until 2012, Dr. Parkinson served as president and chief executive officer of Nodality, a south San Francisco-based biotechnology company focused on the biological characterization of signalling pathways in patients with malignancy to enable more effective therapeutics development and clinical decision-making. Until October, 2007, Dr. Parkinson was senior vice-president, oncology research and development, at Biogen Idec. At Biogen Idec, he oversaw all oncology discovery research efforts and the development of the oncology pipeline. Previously he had served as vice-president, oncology development, at Amgen, and vice-president, global clinical oncology development, at Novartis. During his tenures at Amgen and Novartis, Dr. Parkinson was responsible for clinical development activities, leading to a series of successful global drug registrations for important cancer therapeutics, including Gleevec, Femara, Zometa, Kepivance and Vectibix. Prior to joining industry, Dr. Parkinson worked at the National Cancer Institute from 1990 to 1997, serving as chief of the investigational drug branch, then as acting associate director of the cancer therapy evaluation program. Dr. Parkinson is a past chairman of the Food & Drug Administration (FDA) biologics advisory committee and is a recipient of the FDA's Cody Medal. Dr. Parkinson received his medical degree from the University of Toronto. He completed a hematology fellowship at Royal Victoria Hospital at McGill University in Montreal and was a research fellow at the New England Medical Center at Tufts University in Boston.

David Wood

Mr. David Wood serves as Chief Financial Officer of the Company., He is responsible for managing all financial aspects of the Company, including financial reporting, treasury, and matters related to compliance and corporate governance, insurance, human resources, and facilities. Mr. Wood has over 30 years’ experience in management positions in both large corporations and early stage companies in North America and the U.K. Prior to joining ESSA in 2013, he was Head of Finance and Corporate Development, Secretary and Treasurer at Celator Pharmaceuticals Inc. from 2003 to 2013. Prior to 2003, he was Managing Director of Cubist Pharmaceuticals (UK) Ltd., Senior Director, International Operations of Cubist Pharmaceuticals Inc. and Finance Director at TerraGen Discovery, Inc., Vancouver, B.C. During over 15 years working in the biopharmaceutical industry, he has overseen several merger and acquisition transactions and numerous financings which raised over $100 million. Mr. Wood began his career in the finance and exploration departments at Chevron Corp. He received an M.B.A. from the University of Western Ontario, a B.Sc. Honors in Biology, Queen’s University, and a CPA, CMA accounting designation. Mr. Wood served on the governing body of the National Research Council of Canada from 2008 to 2014. Mr. Wood has entered into a non-disclosure agreement with the Company and his employment agreement contains a non-competition clause.

Peter Virsik

Mr. Peter Virsik is Chief Operating Officer, Executive Vice President of the Company. Prior to joining Essa, Mr. Virsik served as senior vice-president, corporate development, for XenoPort (acquired by Arbor Pharmaceuticals), leading licensing, strategy, new product planning and alliance management for the company. During his tenure at XenoPort, Mr. Virsik played an integral role in the licensing and commercialization of Horizant (gabapentin enacarbil). Prior to XenoPort, Mr. Virsik worked for Gilead Sciences from 2000 through 2005 in corporate development, where he was involved in building Gilead's HIV franchise through the acquisition of Triangle Pharmaceuticals and the licensing of Vitekta (elvitegravir). Before joining Gilead, Mr. Virsik worked at J.P. Morgan in the biotechnology equity research group and as a consultant for Ernst and Young. Mr. Virsik began his career in research and development at Genentech.

Raymond Andersen

Dr. Raymond L. Andersen, (Ray) serves as Chief Technology Officer, Director of the Company. He is the co-founders of ESSA. He has served as the Secretary of the Company since January 2009, and as a director and Chief Technical Officer of the Company since October 2010. He is responsible for participating in the research and development of ESSA’s drug candidates, and with the assessment and review of business and scientific matters. As an independent consultant, he devotes approximately 20% of his time to the affairs of the Company. He is also a Professor at UBC in the departments of Chemistry and Earth & Ocean Sciences. He is internationally known for his research into the identity and structure of novel chemical compounds derived from marine organisms, the molecular routes to their biosynthesis, their role in ocean ecology, and their potential as new drugs. Among them are compounds that have anti-inflammatory and anti-cancer properties and these compounds are being developed as anti-asthma, and anti-tumour drugs. His discoveries represented core technologies of the UBC spinoff companies Aquinox Pharmaceuticals Inc. and Inflazyme Pharmaceuticals. His industrial programs have led to deals with Aventis and Wyeth and the venture capital arms of Johnson & Johnson and Pfizer. Dr. Andersen received his B.Sc. degree from the University of Alberta, a M.Sc. from UC Berkeley, and Ph.D. from U.C. San Diego. He carried out post-doctoral research at the Massachusetts Institute of Technology. In recognition of his pioneering achievements, Dr. Andersen was inducted into the Royal Society of Canada and recently received the R. U. Lemieux Award from the Canadian Society for Chemistry and the Jacob Biely Research Prize from UBC. Dr. Andersen’s consulting agreement contains non-competition and confidentiality clauses.

Marianne Sadar

Dr. Marianne D. Sadar serves as Chief Scientific Officer, Director of the company., she has been co-founders of ESSA. Dr. Sadar has been a director of the Company since January 2009, and has acted as the Chief Scientific Officer of the Company since October 2010. She is responsible for participating in the research and development of ESSA’s drug candidates, and with the assessment and review of business and scientific matters. As an independent consultant, she devotes approximately 20% of her time to the affairs of the Company. She is a Distinguished Scientist at the BC Cancer Agency and a Professor of Pathology and Laboratory Medicine at UBC. Dr. Sadar is internationally known for her research on identifying mechanisms of activating the AR and developing therapeutics for advanced prostate cancer that target the N-terminal domain of the AR. Her research was the first to shoasw that the N-terminal domain of the AR could be activated by alternative pathways and she proposed this domain as a therapeutic target in 1999. Later, Dr. Sadar provided the first proof-of-concept that targeting the N-terminus of the AR results in a therapeutic response in an in vivo model of CRPC. Dr. Sadar received her B.Sc. from Simon Fraser University, and Ph.D. from the University of Bradford, U.K. She carried out post-doctoral training at AstraZeneca (Astra Hässle), Department of Drug Metabolism and Pharmacokinetics in Mölndal, Sweden and at the BC Cancer Agency. She has served on approximately 50 scientific panels, and has been a recipient of awards including the Terry Fox Young Investigator Award, Simon Fraser University Alumni Award for Academic Excellence, and the first non-American to receive the Sosciety of Women in Urology/Society of Basic Urologic Research “Award for Excellence in Urologic Research”. She has served as President of the Society of Basic Urologic Research (USA), member of the Scientific Advisor Boards for the Prostate Cancer Foundation (USA) and Coalition to Cure Prostate Cancer (Canada).

Frank Perabo

Dr. Frank Perabo is a Chief Medical Officer of the Company., since September 2014. He is responsible for developing a clinical advisory board and assisting with the pre-clinical development of ESSA’s product candidate. Dr. Perabo has more than 18 years of experience in preclinical and clinical drug development in Urologic Oncology. Before joining ESSA, he served as Executive Director of Medical Science Oncology for 5 years at Astellas Pharma Global Development, Inc. In this position he was instrumental for the development and global approvals of XTANDI (Enzalutamide). From January 2008 to June 2011, he served as a Director and then Senior Director at Astellas Europe, as Global Medical Lead in Urology, Gynecology and Pain working on preclinical to Phase 3 development, successfully directing Phase-3 programs for OAB and BPH, as well as various other preclinical and clinical compounds in development. From 2001 to 2006, Dr. Perabo worked as independent consultant in business development, and preclinical and clinical R&D. From 2000 to 2001, Dr. Perabo served as Scientific Director at Oncology World, Munich (a specialized CRO in Oncology) establishing clinical development and business strategies. He obtained his training in surgery and urology at the Universities of Munich, Freiburg and Bonn from 1993 to 1999 after graduating from the Medical School at the University of Munich with magna cum laude. He is a board certified urologist, and Associate Professor of Urology at Bonn University (Germany), and a Fellow of the European Board of Urology (FEBU), next to being a member of several Urologic and Oncologic associations. In his career, he has received many awards and grants including an European Commission FP7 (Marie Curie Fellowship) grant, a grant from the Center for Translational Molecular Medicine (CTMM), numerous awards for best scientific presentations, and the prestigious Maximilian-Nitze-Award of the German Urological Society (DGU) work his work on tumor immune escape.

Franklin Berger

Mr. Franklin M. Berger serves as an Director of the Company. Mr. Berger spent 12 years in sell-side equity research, most recently as managing director, U.S. equity research, at J.P. Morgan Securities Inc. from May, 1998, to March, 2003. During his five years at JPM, he was involved with the issuance of over $12-billion in biotechnology company equity or equity-linked securities. The majority of these transactions were book run and lead managed by the JPM biotech team. He was associated with several notable financings in the biotechnology sector, including the Genentech Inc. initial public offering and the first large Celgene Corp. financings, as well as financings of several large-cap biotechnology companies in their rapid growth phase. His team covered 26 publicly traded biotechnology companies. Mr. Berger began his career as a sell-side analyst at Josephthal & Co. in 1991, subsequently moving to Salomon Smith Barney in 1997 serving as director, equity research and senior biotechnology analyst. Mr. Berger currently serves on the board of directors of three public biotechnology companies: Five Prime Therapeutics Inc., Immune Design Corp. and Bellus Health Inc. Previous public company board service included 11 years with Seattle Genetics Inc. and seven years with VaxGen Inc. and Aurinia Pharmaceuticals Inc. (previously Isotechnika Pharma Inc.), based in Canada. He also serves or has served on private biotech company boards of directors, including iTherX Pharma Inc., Caprion Proteomics Inc. (sold in July, 2012) and ViroChem Pharma Inc., which was purchased by Vertex Pharmaceuticals Inc. for $400-million in 2009. Mr. Berger has led multiple merger and acquisition analyses resulting in greater than $1-billion in transaction value.

Scott Requadt

Mr. Scott Requadt, JD is the Director of the Company. He is currently a Managing Director at Clarus Ventures, a life sciences venture capital fund. Scott has over 15 years of operating and investment experience in the pharmaceutical industry. Prior to joining Clarus in 2005, Scott was Director, Business Development of TransForm Pharmaceuticals, and previously practiced for several years as an M&A attorney at the NYC-based law firm of Davis Polk & Wardwell. Before that, Scott was a law clerk for a senior judge at the Supreme Court of Canada. Scott holds a B.Com (Economics & Finance) from McGill University, an LL.B from University of Toronto and an MBA from Harvard Business School (Baker Scholar). Mr. Requadt has been involved in multiple investments spanning both therapeutics and medtech, including Intercept Pharmaceuticals and several R&D risk-sharing collaborations with large pharma partners. He has previously been active on the Boards of TyRx, Catabasis, Oxford Immunotec, VBI Vaccines, Link Medicine and Biolex Therapeutics.

Gary Sollis

Mr. Gary Sollis serves as an Director of the Company. Mr. Sollis is a partner at the law firm of Dentons Canada LLP. He represents clients in the areas of corporate and securities law, with a focus on acquisitions, financings and reorganizations. He has acted for a variety of public and private companies in financing transactions, including public offerings, private placements of debt and equity, special warrant financings and public and private limited partnership offerings. Mr. Sollis has also assisted clients in connection with takeover bids, mergers, proxy contests, spin-offs, joint ventures and acquisitions of private businesses. He received a Bachelor of Laws degree from Dalhousie University.